News
Head over to our 
PROLIFICA Twitter account to keep up-to-date with our research.
Recent news:
28 July 2021
Today, on the 28th of July, World Hepatitis Day, the PROLIFICA research group (Prevention on Liver Fibrosis and Cancer in Africa) would like to express its strong commitment in the fight against viral hepatitis in Africa and in other endemic regions. Millions of people remain undiagnosed and untreated when needed, making the viral hepatitis elimination goals a long way to go. Strategies to improve prevention, screening and treatment are needed.
The image above shows the initiation of HBV antenatal screening in The Gambia.
20 September 2020
Important work from Dr Yusuke Shimakawa informing the WHO 2020 guidelines on the efficacy and safety of peripartum antiviral prophylaxis: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30586-7/fulltext
19 September 2020
Look at our recent assessment of COVID-19 on viral hepatitis services in sub-Saharan Africa published in The Lancet Gastro-Hepatology
10 September 2020
Prevention of MTCT is critical to control the HBV epidemic but remains a major challenge in resource-limited settings. Dr Maud Lemoine discussed suitable strategies to scale up birth dose vaccination and screening of pregnant women at The Conference on Liver Disease in Africa (COLDA).
29 July 2020
Launch of new WHO guidelines for the Hepatitis B prevention of mother-to-child transmission. Cost-effectiveness modelling input from Dr Shevanthi Nayagam https://www.who.int/publications/i/item/978-92-4-000270-8
28 July 2020 - World Hepatitis Day
Check out some articles recently published by our PROLIFICA researchers at Imperial College London:
Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination: https://doi.org/10.1016/j.jhep.2020.06.008
Progress towards elimination goals for viral hepatitis: https://doi.org/10.1038/s41575-020-0332-6
PROLIFICA team member at Imperial College London, Dr Shevanthi Nayagam and colleagues, have worked with the WHO to launch their HBV PMTCT guidelines on World Hepatitis Day 2020. Shevanthi has contributed to the cost-effectiveness modelling of the guidelines. You can read more about the launch here: https://www.who.int/publications/i/item/978-92-4-000270-8
27 July 2020
Ahead of World Hepatitis Day Dr Maud Lemoine has contributed to a new Viewpoint published in Nature Reviews Gastroenterology & Hepatology. The Viewpoint addresses progress made towards the elimination of viral hepatitis as a global health threat as we head towards the 2030 deadline set by the World Health Organization. Dr Lemoine discusses the importance of sustainable funding and the need for simplified diagnostic and treatment algorithms based on inexpensive tests that can be implemented easily in rural areas. You can read more here: https://doi.org/10.1038/s41575-020-0332-6.
18 June 2020
Dr Shevanthi Nayagam and Professor Maud Lemoine have contributed their expertise to the AfraVIH Book launched on 18 June 2020. The book reviews current developments in the fields of HIV, hepatitis and sexual health and more than 190 French-speaking experts in 17 countries have contributed to the publication. For over 10 years AfraVIH have been working to bring together French-speaking healthcare professionals involved in HIV and chronic viral infection research.
28 July 2018
2 July 2018
Following the development of TREAT-B score.
8 August 2017
5 January 2017
Professor Maud Lemoine wrote an article on HBV Screen and Treat.
2016
11 May 2014
Prof. Mourtalla Ka: Hépatite B - une urgence silencieuse au Sénégal
8 May 2014
